Bass, Berry & Sims attorney Susie Bilbro provided insight for an article in SHRM about how President Trump’s new deal related to costs of GLP-1 drugs could impact employers. The high costs of GLP-1 weight loss drugs significantly impacted employer health plan’s prescription drug spending during the past year. In response to the unanticipated high costs, Susie said, “many employers have implemented plan limits for GLP-1 drugs or have eliminated (or are considering eliminating) GLP-1 coverage due to the financial burden on both the organization and employees.”
Trump’s new deal on GLP-1 drugs could lower prices so that actual overall drug spending could increase. Susie “also suggested that if the deal successfully lowers prices for many Americans, it could open the door for negotiations between pharmacy benefit managers and drug manufacturers, which could potentially result in lower costs for employers. This could enable employers to expand or reinstate GLP-1 coverage for their workforce.”
The full article, “What Trump’s Deal on GLP-1 Costs Could Mean for Employers,” was published by SHRM on November 10 and is available online (subscription required).